Abstract
We appreciate the correspondence concerning the NACIAM trial (N-acetylcysteine in Acute Myocardial Infarction),1 which focused on the study analytical methods and potential mechanisms contributing to the benefits of N-acetylcysteine (NAC)/nitroglycerin use in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Original language | English |
---|---|
Pages (from-to) | 1424-1425 |
Number of pages | 2 |
Journal | Circulation |
Volume | 137 |
Issue number | 13 |
DOIs | |
Publication status | Published - 27 Mar 2018 |
Externally published | Yes |
Keywords
- N-acetylcysteine
- Primary percutaneous coronary intervention
- Myocardial infarction